Experimental evidences for role of gel platelet-rich fibrin in treatment of mouse Asherman syndrome

Abstract

Asherman syndrome is recognized by uterine adhesions or fibrosis caused by endometrial injury. This can result in dysmenorrhea, infertility, and pregnancy loss. Platelet-rich fibrin (PRF) contains a large number of platelets and is a source of growth factors, which have been proven to stimulate wound healing, proliferation, and migration of cells. Therefore, PRF is a potential biomaterial for treating endometrial damage. This research was carried out on mice to estimate the effects of gel PRF (gPRF) on damaged endometrium by mechanical force using a 25-gauge needle. The murine model of Asherman syndrome was divided into three groups under any circumstances, including the sham-operated (control) group, the negative control group (PBS group), and the treatment group (gPRF group). The results revealed that one dose of gPRF (20 µL/horn) increased the number of uterine glands, the thickness of the endometrium, and the outcome of pregnancy in the mice’s uterus (P < 0.05). To use gPRF in clinical treatments to recover endometrial damage, this study provides a scientific foundation for that possibility.